葡萄糖代谢率与四维[18F] FDG PET/CT，以区分结节病变与恶性病变

在18F氟氧基葡萄糖（FDG）PET上，活动性结节病变通常很难与恶性病变区分开。我们研究了葡萄糖代谢速率（MRGLC，mg/min/100 mL）的潜力，这是一种基于线性patlak分析的直接重建的葡萄糖代谢动力学的新定量，以区分结节性病和恶性病变的葡萄糖代谢动力学。注册。标准扫描中具有标准化摄取值（SUV）≥2.7的病变作为活性病变。 SUV和MRGLC使用在四维FDG PET/CT上获得30分钟至50分钟的数据得出。测量了兴趣量（1.5 cm3）的平均值。使用MRGLC和SUV对结节病的诊断性能进行了使用接收器 - 手术特征（ROC）分析评估。从44例患者（18名男性，63.4±12.2岁）的44例患者和57名癌症患者的87例恶性病变（32例癌症患者）（32例癌症患者）（32例男性，65例男性，65岁，65岁，65岁）分析分析的总共90例90例垂体病病变。结节病变的SUV和MRGLC明显低于恶性病变的SUV和MRGLC（SUV，4.98±2.00 vs 6.21±2.14; MRGLC，2.52±1.39 vs 3.68±1.61; P <0.01）。 ROC分析表明，在曲线下区分结节患者与恶性肿瘤患者的能力在0.703和0.754下产生了区域，SUV 5.025和MRGLC 2.855的敏感性分别为64％和77％，特异性为75％和72％。单独使用SUV的鉴定。MRGLC可以单独改善SUV的结节淋巴结鉴定，并有望通过消除延迟的扫描来缩短检查时间。活性的结节病变有时与FDG积累有关，应与恶性病变区分。葡萄糖（MRGLC）的SUV和代谢速率密切相关，MRGLC可以区分结节病变和恶性病变。 MRGLC允许对恶性病变进行准确的评估和分期。

On 18F-Fludeoxyglucose (FDG) PET/CT, active sarcoid lesions are often difficult to differentiate from malignant lesions. We investigated the potential of the glucose metabolic rate (MRglc, mg/min/100 mL), a new quantification of glucose metabolic kinetics derived from direct reconstruction based on linear Patlak analysis, to distinguish between sarcoidosis and malignant lesions.A total of 100 patients with cardiac sarcoidosis (CS) and 67 patients with cancer who underwent four-dimensional FDG PET/CT were enrolled. The lesions with a standardized uptake value (SUV) ≥ 2.7 on the standard scan were included as active lesions in the analysis. SUV and MRglc were derived using data acquired between 30 min and 50 min on four-dimensional FDG PET/CT. The mean value in the volume of interest (size 1.5 cm3) was measured. The diagnostic performance of sarcoidosis using MRglc and SUV was evaluated using receiver-operating-characteristic (ROC) analysis.A total of 90 sarcoidosis lesions from 44 CS patients (18 males, 63.4 ± 12.2 years) and 87 malignant lesions from 57 cancer-bearing patients (32 males, 65 ± 14 years) were analyzed. SUV and MRglc for sarcoid lesions were significantly lower than those for malignant lesions (SUV, 4.98 ± 2.00 vs 6.21 ± 2.14; MRglc, 2.52 ± 1.39 vs 3.68 ± 1.61; p < 0.01). ROC analysis indicated that the ability to discriminate sarcoid patients from those with malignancy yielded areas under the curves of 0.703 and 0.754, with sensitivities of 64% and 77% and specificities of 75% and 72% for SUV 5.025 and MRglc 2.855, respectively.MRglc was significantly lower in sarcoid lesions than malignant lesions, and improved sarcoid lesions identification over SUV alone.MRglc improves sarcoid lymph node identification over SUV alone and is expected to shorten the examination time by eliminating delayed scans.Active sarcoid lesions are sometimes associated with FDG accumulation and should be differentiated from malignant lesions. SUV and metabolic rate of glucose (MRglc) strongly positively correlated, and MRglc could differentiate sarcoid and malignant lesions. MRglc allows for accurate evaluation and staging of malignant lesions.